Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Hydroxyzine: adverse event reports

All products with this active ingredient · not in an FDA-approved animal drug

1,060reports naming this ingredient, 2001–20260.1% of all reports · about 42 a year
47reports, 12 months to March 202645 in the 12 months before
31.8%classed serious, as reportedof 1,047 reports stating it
4.2%record death or euthanasia, as reported44 reports
96.8%of reports concern dogs0.1% of all dog reports

Between February 2001 and March 2026 FDA received 1,060 adverse event reports listing a drug with hydroxyzine as the recorded active ingredient. It is not the active ingredient of an FDA-approved animal drug; it reaches animals through human-label or compounded products.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 47 reports named it, close to the 45 of the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 42 reports a year and 0.1% of all 1,357,245 reports (0.1% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The most frequently coded terms are emesis (21.8%), vomiting (16.5%) and lethargy (14.8%). A report can list several signs, so shares add to more than 100%; 788 different terms appear across these reports.

96.8% of reports concern dogs. Not every report describes illness: 15.7% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 31.8% were classed as serious, and 4.2% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog162 · peak 9
Apr 2021: 4May 2021: 3Jun 2021: 3Jul 2021: 2Sep 2021: 2Nov 2021: 7Jan 2022: 1Feb 2022: 5Mar 2022: 4Apr 2022: 1May 2022: 1Jun 2022: 6Jul 2022: 1Aug 2022: 2Sep 2022: 2Oct 2022: 3Dec 2022: 1Feb 2023: 1Mar 2023: 2Apr 2023: 2May 2023: 1Jun 2023: 2Aug 2023: 3Sep 2023: 3Oct 2023: 2Nov 2023: 5Dec 2023: 4Feb 2024: 1Mar 2024: 3Apr 2024: 2May 2024: 1Jun 2024: 3Jul 2024: 6Aug 2024: 4Sep 2024: 4Oct 2024: 5Nov 2024: 1Dec 2024: 1Jan 2025: 3Feb 2025: 6Mar 2025: 4Apr 2025: 9May 2025: 4Jun 2025: 5Jul 2025: 3Aug 2025: 1Sep 2025: 9Oct 2025: 7Nov 2025: 1Dec 2025: 2Feb 2026: 3Mar 2026: 12022202320242025
Cat5 · peak 1
Jun 2023: 1Jul 2023: 1Mar 2024: 1May 2024: 1Dec 2025: 12022202320242025
Horse2 · peak 1
Jul 2023: 1Feb 2025: 12022202320242025
Other5 · peak 2
Oct 2023: 1Apr 2024: 2Nov 2024: 1Aug 2025: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

0941882001: 120012003: 12007: 120072011: 222012: 18520122013: 1882014: 10520142015: 932016: 12420162017: 762018: 3920182019: 232020: 1920202021: 302022: 2720222023: 292024: 3620242025: 572026: 42026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of hydroxyzine reports listing the termall dog reports

  1. Emesis[vomiting]21.8%231
  2. Vomiting16.5%175
  3. Lethargy[unusually tired or inactive]14.8%157
  4. Diarrhoea[diarrhea]8.4%89
  5. Other abnormal test result NOS[abnormal laboratory result, type not specified]7.7%82
  6. Lack of efficacy - NOS[the product did not have the expected effect]7.3%77
  7. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]4.3%46
  8. Behavioural disorder NOS[behaviour change, type not specified]4.2%45
  9. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]4.2%44
  10. Seizure NOS[seizure, type not specified]4.1%43
  11. Anorexia[not eating]4%42
  12. Pruritus[itching]3.4%36
  13. Ineffective, atopy control[legacy FDA term: the product did not have the expected effect (atopy control)]3.1%33
  14. Panting2.8%30
  15. Polydipsia[drinking more than usual]2.8%30
  16. Ataxia[unsteady, uncoordinated movement]2.7%29
  17. Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]2.6%28
  18. Polyuria[passing more urine than usual]2.5%27
  19. Shaking2.5%27
  20. Death by euthanasia[the animal was euthanized]2.3%24
  21. Leucocytosis NOS[high white blood cell count]2%21
  22. Skin lesion NOS[NOS: not otherwise specified]2%21
  23. Fever1.9%20
  24. Leucopenia NOS[low white blood cell count]1.8%19
  25. Overdose[more than the labelled amount was given]1.8%19

Top 30 of 788 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal42.5%451
Recovered with Sequela3.9%41
Ongoing30.6%324
Died2%21
Euthanized2.2%23
Outcome Unknown18.2%193

What kind of report it was

Safety issue80.8%856
Lack of expected effectiveness6.8%72
Both safety and lack of expected effectiveness8.9%94
Manufacturing or product defect3.6%38
Other0%0

Coloured bar: reports naming hydroxyzine. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog96.8%1,026
Cat1.5%16
Human exposure0.9%10
Horse0.3%3

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year4.4%47
1 to 3 years19.9%211
4 to 7 years34%360
8 to 11 years26.4%280
12 years and over13%138
Age not given2.3%24

Weight of the animal

Under 5 kg (11 lb)9.3%99
5 to 9.9 kg (11–22 lb)29.5%313
10 to 24.9 kg (22–55 lb)28%297
25 to 44.9 kg (55–99 lb)27.2%288
45 kg and over (99 lb+)3.6%38
Weight not given2.4%25

Route of administration stated in reports: oral (648), ophthalmic (1).

In context

MeasureHydroxyzineAll dog reportsAll reports
Reports1,060985,6751,357,245
Share of that pool's reports naming this drug—0.1%0.1%
Classed serious, of reports stating it31.8%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports41.55563.8
Filed as lack of expected effectiveness (wholly or partly)15.7%—23%
Top term, share of reportsEmesis 21.8%6.5%—

This set accounts for 99.9% of all reports naming hydroxyzine, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

The Green Book lists no approved animal drug with these ingredients. Reports reach FDA for human-label and compounded drugs that veterinarians prescribe.

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about hydroxyzine reports

How many adverse event reports has FDA received for hydroxyzine?

1,060 reports record a drug with hydroxyzine as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 47 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

emesis (21.8%), vomiting (16.5%), lethargy (14.8%), diarrhoea (8.4%) and other abnormal test result NOS (7.7%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (96.8%), cat (1.5%) and human exposure (0.9%). Among single-breed animals the most frequent labels are Labrador Retriever, Shih Tzu, Yorkshire Terrier and Golden Retriever; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

47 reports in the 12 months to March 2026, close to the 45 of the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that hydroxyzine harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of hydroxyzine?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.